Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
Mayoly Spindler completed the acquisition of Ipsen's CHC branch - MAYOLY SPINDLER laboratoire indépendant français
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
Press Releases - Ipsen UK
Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Ipsen CEO steers clear of gene therapy despite rare disease push
Press Releases - Ipsen UK
Press Releases - Ipsen UK
Combined Shareholders' Meeting of 27 May 2021
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3 | Business Wire
Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts | Financial Post
Ipsen Goes All In on Neuro with $1 Billion+ Deal For Exicure's Oligonucleotides | BioSpace
Press Releases - Ipsen UK
Press Releases - Ipsen UK
Ipsen media library
Ipsen: a dynamic, fast-growing specialty care powerhouse
Emirates Oncology Society And Ipsen Break Guinness World Record For Largest Awareness Ribbon | Press Release Network
LeaveRussia: Ipsen is Pausing New Investments in Russia
Ipsen puts patients first
Gebrüder Weiss takes over Ipsen Logistics' Air & Sea business | DC Velocity
FOP Fnd NL on X: "Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies ...for children under the age of 14 because of some cases with early growth plate closure...
Ipsen Inc. | Aviation Pros
Ipsen's quick fix backfires | Evaluate
Paul van Doesburg, CEO, Ipsen, Germany | The Monty
06-01-2016-PR-Ipsen-Galderma-APAC-Dysport-Aesthetics
